Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 3/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2250573 | 0.94 | SMARCA2 (0.41) | SMARCA2SMARCA4KMT2AMEN1MAPT | |
| SCHEMBL5016707 | 0.89 | SMARCA2 (0.39) | SMARCA2SMARCA4KMT2AMEN1MAPT | |
| SCHEMBL5016676 | 0.89 | SMARCA2 (0.39) | SMARCA2SMARCA4KMT2AMEN1MAPT | |
| SCHEMBL2251440 | 0.89 | SMARCA2 (0.39) | SMARCA2SMARCA4KMT2AMEN1MAPT | |
| SCHEMBL2254860 | 0.88 | SMARCA2 (0.39) | SMARCA2SMARCA4KMT2AMEN1MAPT | |
| SCHEMBL3204580 | 0.86 | NPSR1 (0.41) | KMT2AMEN1MAPTMAPK8MAPK9 | |
| SCHEMBL3199885 | 0.84 | RORC (0.47) | SMARCA2SMARCA4KMT2AMEN1MAPT | |
| SCHEMBL2254757 | 0.84 | SMARCA2 (0.39) | SMARCA2SMARCA4KMT2AMEN1MAPT | |
| SCHEMBL3187925 | 0.83 | RORC (0.41) | SMARCA2SMARCA4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3189481 | 0.83 | RORC (0.41) | SMARCA2SMARCA4NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197497-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | claimed |
| EP-1962852-B1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20070197497-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197497-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | SMARCA2 959/4885SMARCA4 964/4885KMT2A 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.